Content about Lipitor

February 15, 2012

Managed care and prescription plans are working to switch patients to generic versions of Pfizer's Lipitor despite the drug maker's efforts to reduce costs for the branded version, a new study suggested.

PHOENIX — Managed care and prescription plans are working to switch patients to generic versions of Pfizer's Lipitor despite the drug maker's efforts to reduce costs for the branded version, a new study suggested.

According to a report released Wednesday by Wolters Kluwer Pharma Solutions' inThought research group, while Lipitor (atorvastatin) has 41% of the market share of all dispensed prescriptions of atorvastatin, it has 35% of the payer approval volume.

February 2, 2012

The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Mylan, the drug maker said Thursday.

PITTSBURGH — The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Mylan, the drug maker said Thursday.

Mylan announced that it had received tentative approval for a generic version of Pfizer's Lipitor (atorvastatin calcium) in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

February 1, 2012

For the past several years, drug industry experts have spoken in terms of the “patent cliff,” the period when the patents covering several blockbuster drugs are set to expire, thus leaving their manufacturers with a big, gaping hole in their revenues as those drugs face competition from generics.

For the past several years, drug industry experts have spoken in terms of the “patent cliff,” the period when the patents covering several blockbuster drugs are set to expire, thus leaving their manufacturers with a big, gaping hole in their revenues as those drugs face competition from generics.

January 20, 2012

One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

WHAT IT MEANS AND WHY IT'S IMPORTANT — One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

January 20, 2012

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

January 20, 2012

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


January 3, 2012

Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said.

SUPPLIER NEWS — Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said. The features will give pharmacies an outreach channel to improve their bin management and will-call services, as well as allow them to easily identify aging prescriptions and use the Mscripts mobile application to remind customers to pick up their prescriptions.


December 23, 2011

Rather than take off for Christmas, the editors of Drug Store News took a look at the year ahead and the stories, issues and trends that will make headlines in retail pharmacy in 2012.

Rather than take off for Christmas, the editors of Drug Store News took a look at the year ahead and the stories, issues and trends that will make headlines in retail pharmacy in 2012.

December 13, 2011

Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

NEW YORK — Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy's generic atorvastatin calcium tablets and Watson Pharmaceuticals' authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.

December 6, 2011

Days after its launch of a generic version of Pfizer's cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

PRINCETON, N.J. — Days after its launch of a generic version of Pfizer's cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.

December 5, 2011

With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

WHAT IT MEANS AND WHY IT'S IMPORTANT — With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

December 1, 2011

Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

SILVER SPRING, Md. — Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

The FDA announced the approval of Ranbaxy's atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths. New Brunswick, N.J.-based Ohm Labs will manufacture the drug.

December 1, 2011

Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

NEW YORK — Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

The New York Times reported Thursday that three senators — Max Baucus, D-Mont.; Chuck Grassley, R-Iowa; and Herb Kohl, D-Wis. — had asked Pfizer and five other companies to provide details of their agreements to prevent dispensing of generic versions of Lipitor (atorvastatin) and dispense only the branded version.

November 30, 2011

Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.

NEW YORK — Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.

November 23, 2011

Pfizer is looking to sell its top-selling cholesterol drug directly to consumers at a greatly reduced price after the patent expires, according to published reports.

NEW YORK — Pfizer is looking to sell its top-selling cholesterol drug directly to consumers at a greatly reduced price after the patent expires, according to published reports.

The Wall Street Journal reported that Pfizer would partner with health plans to sell Lipitor (atorvastatin) directly to consumers through the mail when the drug's patent expires at the end of the month, opening the drug to generic competition.

November 16, 2011

When its blockbuster cholesterol drug Lipitor loses patent protection this month, Pfizer is hoping that pharmacy benefit managers will not dispense a generic version of the drug to its customers, according to published reports.

NEW YORK — When its blockbuster cholesterol drug Lipitor loses patent protection this month, Pfizer is hoping that pharmacy benefit managers will not dispense a generic version of the drug to its customers, according to published reports.

Pharmacy benefit managers Medco and Catalyst have agreed to block generic versions of Lipitor from reaching their customers until the end of May 2012, according to Bloomberg. Additionally, the company reportedly is in talks with Express Scripts to have the PBM also block generic versions from reaching customers as well.

November 4, 2011

In February, Drug Store News discussed three issues concerning generic drugs that would figure prominently throughout the year: drug safety, user fees and patent settlements.


In February, Drug Store News discussed three issues concerning generic drugs that would figure prominently throughout the year: drug safety, user fees and patent settlements.


November 2, 2011

It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

NEW YORK — It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

September 12, 2011


As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 



As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 


September 12, 2011

At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


September 8, 2011

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

NEW YORK — Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

Citing Japan's Nikkei daily, Reuters reported that Gurgaon, India-based Ranbaxy would launch a generic version of Pfizer's cholesterol medication Lipitor (atorvastatin) at the end of November.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

August 19, 2011

While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

NEW YORK — While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

Citing Credit Suisse analysts, Bloomberg reported that the FDA may delay approval of Ranbaxy's version of Lipitor (atorvastatin), which would prevent it from marketing the drug starting Nov. 30, as it has planned to do.

August 17, 2011

Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

ALLEGAN, Mich. — Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

And while none of these new over-the-counter private-label products will help reduce cholesterol levels, Papa did set the stage for a future store-brand equivalent to Pfizer's blockbuster statin Lipitor.

August 4, 2011

The world's top-selling drug may become available over the counter, if its manufacturer has its way, according to published reports.

NEW YORK — The world's top-selling drug may become available over the counter, if its manufacturer has its way, according to published reports.

The New York Times reported that Pfizer may be looking for Food and Drug Administration approval for an OTC switch for Lipitor (atorvastatin calcium), a cholesterol-lowering medication. The Times quoted an unnamed source as providing the information, though Pfizer declined to comment.